
## Michael J Mullan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3101006/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sex-specific differences in plasma lipid profiles are associated with Gulf War Illness. Journal of Translational Medicine, 2022, 20, 73.	1.8	5
2	Exogenous lipase administration alters gut microbiota composition and ameliorates Alzheimer's disease-like pathology in APP/PS1 mice. Scientific Reports, 2022, 12, 4797.	1.6	6
3	Adaptive Immune Responses Associated with the Central Nervous System Pathology of Gulf War Illness. Neuroscience Insights, 2021, 16, 263310552110184.	0.9	6
4	Mural cell dysfunction leads to altered cerebrovascular tau uptake following repetitive head trauma. Neurobiology of Disease, 2021, 150, 105237.	2.1	12
5	Novel, natural allosteric inhibitors and enhancers of Candida rugosa lipase activity. Bioorganic Chemistry, 2021, 109, 104732.	2.0	3
6	MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer's disease. BMC Neuroscience, 2021, 22, 39.	0.8	25
7	Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy. Frontiers in Aging Neuroscience, 2021, 13, 658605.	1.7	11
8	Influence of traumatic brain injury on extracellular tau elimination at the blood–brain barrier. Fluids and Barriers of the CNS, 2021, 18, 48.	2.4	8
9	Candida rugosa lipase alters the gastrointestinal environment in wild-type mice. Biomedicine and Pharmacotherapy, 2020, 130, 110579.	2.5	3
10	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. Frontiers in Neurology, 2020, 11, 149.	1.1	14
11	Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimer's disease. Neurobiology of Aging, 2020, 95, 56-68.	1.5	13
12	Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model. NeuroToxicology, 2020, 79, 84-94.	1.4	23
13	Unbiased Proteomic Approach Identifies Pathobiological Profiles in the Brains of Preclinical Models of Repetitive Mild Traumatic Brain Injury, Tauopathy, and Amyloidosis. ASN Neuro, 2020, 12, 175909142091476.	1.5	7
14	Chronic White Matter Degeneration, but No Tau Pathology at One-Year Post-Repetitive Mild Traumatic Brain Injury in a Tau Transgenic Model. Journal of Neurotrauma, 2019, 36, 576-588.	1.7	40
15	A permethrin metabolite is associated with adaptive immune responses in Gulf War Illness. Brain, Behavior, and Immunity, 2019, 81, 545-559.	2.0	31
16	Distinct Signaling Pathways Regulate TREM2 Phagocytic and NFκB Antagonistic Activities. Frontiers in Cellular Neuroscience, 2019, 13, 457.	1.8	61
17	A fast, miniaturised <i>in-vitro</i> assay developed for quantification of lipase enzyme activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1474-1480.	2.5	5
18	APOE Genotype Specific Effects on the Early Neurodegenerative Sequelae Following Chronic Repeated Mild Traumatic Brain Injury. Neuroscience, 2019, 404, 297-313.	1.1	25

#	Article	IF	CITATIONS
19	Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier. Molecular Neurobiology, 2019, 56, 8296-8305.	1.9	19
20	Converging and Differential Brain Phospholipid Dysregulation in the Pathogenesis of Repetitive Mild Traumatic Brain Injury and Alzheimer's Disease. Frontiers in Neuroscience, 2019, 13, 103.	1.4	33
21	Impact of Repetitive Mild Traumatic Brain Injury on Behavioral and Hippocampal Deficits in a Mouse Model of Chronic Stress. Journal of Neurotrauma, 2019, 36, 2590-2607.	1.7	16
22	Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury. Annals of Clinical and Translational Neurology, 2018, 5, 64-80.	1.7	110
23	Unbiased Proteomic Approach Identifies Unique and Coincidental Plasma Biomarkers in Repetitive mTBI and AD Pathogenesis. Frontiers in Aging Neuroscience, 2018, 10, 405.	1.7	9
24	Subchronic Pathobiological Response Following Chronic Repetitive Mild Traumatic Brain Injury in an Aged Preclinical Model of Amyloid Pathogenesis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1144-1162.	0.9	2
25	Disruption in Brain Phospholipid Content in a Humanized Tau Transgenic Model Following Repetitive Mild Traumatic Brain Injury. Frontiers in Neuroscience, 2018, 12, 893.	1.4	18
26	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	3.9	131
27	Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness. Scientific Reports, 2018, 8, 12921.	1.6	36
28	Impact of age on acute post-TBI neuropathology in mice expressing humanized tau: a Chronic Effects of Neurotrauma Consortium study. Brain Injury, 2018, 32, 1285-1294.	0.6	25
29	Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 1676-1691.	1.7	29
30	Mild TBI Results in a Long-Term Decrease in Circulating Phospholipids in a Mouse Model of Injury. NeuroMolecular Medicine, 2017, 19, 122-135.	1.8	46
31	Negative Impact of Female Sex on Outcomes from Repetitive Mild Traumatic Brain Injury in hTau Mice Is Age Dependent: A Chronic Effects of Neurotrauma Consortium Study. Frontiers in Aging Neuroscience, 2017, 9, 416.	1.7	26
32	Phospholipid profiling of plasma from GW veterans and rodent models to identify potential biomarkers of Gulf War Illness. PLoS ONE, 2017, 12, e0176634.	1.1	39
33	APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease. Aging, 2017, 9, 964-985.	1.4	58
34	Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury. PLoS ONE, 2016, 11, e0153608.	1.1	40
35	Translational potential of long-term decreases in mitochondrial lipids in a mouse model of Gulf War Illness. Toxicology, 2016, 372, 22-33.	2.0	50
36	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open, 2016, 6, e011584.	0.8	21

#	Article	IF	CITATIONS
37	Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers. Journal of Neuropathology and Experimental Neurology, 2016, 75, 636-655.	0.9	104
38	Plasma Lipidomic Profiling in a Military Population of Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder with Apolipoprotein E ɛ4–Dependent Effect. Journal of Neurotrauma, 2016, 33, 1331-1348.	1.7	43
39	Gulf War Agent Exposure Causes Impairment of Long-Term Memory Formation and Neuropathological Changes in a Mouse Model of Gulf War Illness. PLoS ONE, 2015, 10, e0119579.	1.1	68
40	Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. PLoS ONE, 2015, 10, e0128224.	1.1	26
41	Ultrastructural Changes in the White and Gray Matter of Mice at Chronic Time Points After Repeated Concussive Head Injury. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1012-1035.	0.9	54
42	Neurobehavioral, neuropathological and biochemical profiles in a novel mouse model of co-morbid post-traumatic stress disorder and mild traumatic brain injury. Frontiers in Behavioral Neuroscience, 2014, 8, 213.	1.0	46
43	Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing. NeuroMolecular Medicine, 2014, 16, 686-696.	1.8	41
44	The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation. Journal of Biological Chemistry, 2014, 289, 33927-33944.	1.6	84
45	Lipidomic analyses identify injuryâ€ <b>s</b> pecific phospholipid changes 3 mo after traumatic brain injury. FASEB Journal, 2014, 28, 5311-5321.	0.2	85
46	Exposure to an organophosphate pesticide, individually or in combination with other <scp>G</scp> ulf <scp>W</scp> ar agents, impairs synaptic integrity and neuronal differentiation, and is accompanied by subtle microvascular injury in a mouse model of <scp>G</scp> ulf <scp>W</scp> ar agent exposure. Neuropathology, 2014, 34, 109-127.	0.7	64
47	Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. Annals of Neurology, 2014, 75, 241-254.	2.8	298
48	Repetitive Mild Traumatic Brain Injury Causes Optic Nerve and Retinal Damage in a Mouse Model. Journal of Neuropathology and Experimental Neurology, 2014, 73, 345-361.	0.9	76
49	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open, 2014, 4, e006364.	0.8	47
50	Role of the cannabinoid system in the transit of beta-amyloid across the blood–brain barrier. Molecular and Cellular Neurosciences, 2013, 56, 255-262.	1.0	39
51	Effect of Venlafaxine and Desvenlafaxine on Drug Efflux Protein Expression and Biodistribution In Vivo. Journal of Pharmaceutical Sciences, 2013, 102, 3838-3843.	1.6	21
52	Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Blood–Brain Barrier. Journal of Molecular Neuroscience, 2013, 49, 270-276.	1.1	38
53	Chronic elevation of phosphocholine containing lipids in mice exposed to Gulf War agents pyridostigmine bromide and permethrin. Neurotoxicology and Teratology, 2013, 40, 74-84.	1.2	62
54	A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier. Neurodegenerative Diseases, 2013, 11, 13-21.	0.8	42

#	Article	IF	CITATIONS
55	Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. European Journal of Pharmacology, 2013, 698, 145-153.	1.7	45
56	Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine. PLoS ONE, 2013, 8, e55392.	1.1	36
57	Apolipoprotein E genotypeâ€specific shortâ€ŧerm cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients—an openâ€ŀabel trial. International Journal of Geriatric Psychiatry, 2012, 27, 415-422.	1.3	33
58	Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model. Journal of Neurotrauma, 2012, 29, 246-260.	1.7	31
59	Repetitive Mild Traumatic Brain Injury in a Mouse Model Produces Learning and Memory Deficits Accompanied by Histological Changes. Journal of Neurotrauma, 2012, 29, 2761-2773.	1.7	269
60	Lipidomic Profiling of Phosphocholine Containing Brain Lipids in Mice with Sensorimotor Deficits and Anxiety-Like Features After Exposure to Gulf War Agents. NeuroMolecular Medicine, 2012, 14, 349-361.	1.8	79
61	Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging, 2012, 4, 590-605.	1.4	163
62	Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer's disease. Cytokine, 2011, 53, 163-169.	1.4	43
63	Extended results of the Alzheimer's disease antiâ€inflammatory prevention trial. Alzheimer's and Dementia, 2011, 7, 402-411.	0.4	290
64	Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serumβ-Amyloid. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	5
65	Selective Antihypertensive Dihydropyridines Lower AÎ <sup>2</sup> Accumulation by Targeting both the Production and the Clearance of AÎ <sup>2</sup> across the Blood-Brain Barrier. Molecular Medicine, 2011, 17, 149-162.	1.9	104
66	Epitope-Dependent Effects of Beta-Amyloid Antibodies on Beta-Amyloid Clearance in an In Vitro Model of the Blood-Brain Barrier. Microcirculation, 2011, 18, 373-379.	1.0	9
67	Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier. European Journal of Pharmacology, 2011, 659, 124-129.	1.7	61
68	Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. European Journal of Pharmacology, 2011, 670, 384-391.	1.7	51
69	Proteomic CNS Profile of Delayed Cognitive Impairment in Mice Exposed to Gulf War Agents. NeuroMolecular Medicine, 2011, 13, 275-288.	1.8	69
70	Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharmaceutics and Drug Disposition, 2011, 32, 233-244.	1.1	43
71	Flavonoids lower Alzheimer's Aß production via an NFkB dependent mechanism. Bioinformation, 2011, 6, 229-236.	0.2	39
72	Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Cytotechnology, 2010, 62, 519-529.	0.7	30

#	Article	IF	CITATIONS
73	Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Aβ Peptide. International Journal of Peptide Research and Therapeutics, 2010, 16, 23-30.	0.9	5
74	Alzheimer's βâ€amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFRâ€2. Journal of Neurochemistry, 2010, 112, 66-76.	2.1	84
75	Impaired Orthotopic Glioma Growth and Vascularization in Transgenic Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2010, 30, 11251-11258.	1.7	25
76	Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2010, 7, 17.	3.1	148
77	A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (Aβ) production. Bioinformation, 2010, 5, 122-127.	0.2	6
78	High Serum Aβ and Vascular Risk Factors in First-Degree Relatives of Alzheimer's Disease Patients. Molecular Medicine, 2009, 15, 95-100.	1.9	16
79	Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort. Molecular Medicine, 2009, 15, 432-437.	1.9	19
80	Serum β-Amyloid Correlates with Neuropsychological Impairment. Aging, Neuropsychology, and Cognition, 2009, 16, 203-218.	0.7	17
81	CD40/CD40L interaction induces AÎ <sup>2</sup> production and increases Î <sup>3</sup> -secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Experimental Cell Research, 2009, 315, 2265-2274.	1.2	8
82	Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. International Journal of Geriatric Psychiatry, 2009, 24, 197-201.	1.3	419
83	Structural optimization of a CXCR2-directed antagonist that indirectly inhibits Î <sup>3</sup> -secretase and reduces AÎ <sup>2</sup> . Bioorganic and Medicinal Chemistry, 2009, 17, 8102-8112.	1.4	16
84	A Novel Physico-Chemical Property Based Model for Studying the Effects of Mutation on the Aggregation of Peptides. Protein and Peptide Letters, 2009, 16, 991-998.	0.4	0
85	Proteomic Analysis of Human Neuronal Cells Treated with the Gulf War Agent Pyridostigmine Bromide. Journal of Proteomics and Bioinformatics, 2009, 02, 439-444.	0.4	2
86	CD40 ligation mediates plaque-associated tau phosphorylation in β-amyloid overproducing mice. Brain Research, 2008, 1231, 132-142.	1.1	10
87	The granulocyte macrophage colony stimulating factor (GM-CSF) regulates amyloid β (Aβ) production. Cytokine, 2008, 42, 336-344.	1.4	16
88	Diagnostic utility of APOE, soluble CD40, CD40L, and Aβ1–40 levels in plasma in Alzheimer's disease. Cytokine, 2008, 44, 283-287.	1.4	37
89	Novel Role of CXCR2 in Regulation of Î <sup>3</sup> -Secretase Activity. ACS Chemical Biology, 2008, 3, 777-789.	1.6	40
90	Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Archives of Neurology, 2008, 65, 896.	4.9	354

6

#	Article	IF	CITATIONS
91	Potent anti-angiogenic motifs within the Alzheimer Î <sup>2</sup> -amyloid peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 5-19.	1.4	15
92	Neuropsychological Comparison of Alzheimer's Disease and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2007, 23, 120-125.	0.7	42
93	Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells. Neurochemistry International, 2007, 50, 69-73.	1.9	69
94	Inhibition of AÎ <sup>2</sup> production by NF-Î <sup>2</sup> B inhibitors. Neuroscience Letters, 2007, 415, 11-16.	1.0	79
95	The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels. Neuroscience Letters, 2007, 428, 53-58.	1.0	34
96	CD40 promotion of amyloid beta production occurs via the NF-κB pathway. European Journal of Neuroscience, 2007, 25, 1685-1695.	1.2	19
97	Genomic analysis of response to traumatic brain injury in a mouse model of Alzheimer's disease (APPsw). Brain Research, 2007, 1185, 45-58.	1.1	18
98	CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. Journal of Neuroinflammation, 2006, 3, 3.	3.1	26
99	The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease. Neuroscience Letters, 2006, 395, 240-243.	1.0	38
100	Cocaine induced inflammatory response in human neuronal progenitor cells. Journal of Neurochemistry, 2006, 97, 662-674.	2.1	16
101	Beneficial Effect of Cholinesterase Inhibitor Medications on Recognition Memory Performance in Mild to Moderate Alzheimer's Disease: Preliminary Findings. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 13-15.	1.2	10
102	Inhibition of angiogenesis and tumor growth by β and γ-secretase inhibitors. European Journal of Pharmacology, 2005, 514, 1-15.	1.7	86
103	Model of Alzheimer's disease amyloid-β peptide based on a RNA binding protein. Biochemical and Biophysical Research Communications, 2005, 332, 585-592.	1.0	17
104	Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. Journal of Neuroinflammation, 2005, 2, 9.	3.1	262
105	Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Research, 2004, 999, 53-61.	1.1	77
106	Behavioral effects of CD40–CD40L pathway disruption in aged PSAPP mice. Brain Research, 2004, 1015, 161-168.	1.1	37
107	Inhibition of Angiogenesis by AÂ Peptides. Angiogenesis, 2004, 7, 75-85.	3.7	119
108	No association between subjective memory complaints and apolipoprotein E genotype in cognitively intact elderly. International Journal of Geriatric Psychiatry, 2004, 19, 1131-1139.	1.3	31

#	Article	IF	CITATIONS
109	Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neuroscience Letters, 2004, 366, 80-85.	1.0	121
110	Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor. Cancer Research, 2004, 64, 3586-3592.	0.4	65
111	Apolipoprotein E polymorphism and age of onset for Alzheimer's disease in a bi-ethnic sample. International Psychogeriatrics, 2004, 16, 317-326.	0.6	14
112	Increased TNFα production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. Neuroscience Letters, 2003, 353, 66-68.	1.0	22
113	Vasoactive effects of Aβin isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: Role of inflammation. Neurological Research, 2003, 25, 642-651.	0.6	112
114	Differences in Executive Functioning Between Alzheimer's Disease and Subcortical Ischemic Vascular Dementia. Journal of Clinical and Experimental Neuropsychology, 2002, 24, 745-754.	0.8	53
115	Memory Patterns and Executive Functioning in Mild Cognitive Impairment and Alzheimer's Disease. Aging, Neuropsychology, and Cognition, 2002, 9, 288-297.	0.7	58
116	Apolipoprotein E Polymorphism and Cognitive Impairment in A Bi-Ethnic Community-Dwelling Elderly Sample. Alzheimer Disease and Associated Disorders, 2002, 16, 8-14.	0.6	13
117	Apolipoprotein E Genotype and Cognitive Impairment in Community-Dwelling Black Older Adults. International Journal of Psychiatry in Medicine, 2002, 32, 55-67.	0.8	4
118	Statins inhibit AÎ <sup>2</sup> -neurotoxicity in vitro and AÎ <sup>2</sup> -induced vasoconstriction and inflammation in rat aortae. Atherosclerosis, 2002, 161, 293-299.	0.4	32
119	Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain. Prostaglandins and Other Lipid Mediators, 2002, 70, 1-12.	1.0	41
120	CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. Journal of Neuroimmunology, 2002, 132, 164-172.	1.1	52
121	Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nature Neuroscience, 2002, 5, 1288-1293.	7.1	196
122	Association between Alzheimer's Disease and a Functional Polymorphism in the Myeloperoxidase Gene. Experimental Neurology, 2001, 167, 456-459.	2.0	59
123	CD40 signaling and Alzheimer's disease pathogenesis. Neurochemistry International, 2001, 39, 371-380.	1.9	60
124	Characterization of murine immunoglobulin G antibodies against human amyloid-β1–42. Neuroscience Letters, 2001, 307, 101-104.	1.0	73
125	Molecular genetics of Alzheimer's disease: the role of β-amyloid and the presenilins. Current Opinion in Neurology, 2000, 13, 377-384.	1.8	75
126	Abeta Vasoactivity: An Inflammatory Reaction. Annals of the New York Academy of Sciences, 2000, 903, 97-109.	1.8	29

#	Article	IF	CITATIONS
127	beta-Amyloid Vasoactivity and Proinflammation in Microglia Can Be Blocked by cGMP-Elevating Agents. Annals of the New York Academy of Sciences, 2000, 903, 446-450.	1.8	24
128	Elevated Aβ and Apolipoprotein E in AβPP Transgenic Mice and Its Relationship to Amyloid Accumulation in Alzheimer's Disease. Molecular Medicine, 2000, 6, 430-439.	1.9	73
129	CD45 Inhibits CD40L-induced Microglial Activation via Negative Regulation of the Src/p44/42 MAPK Pathway. Journal of Biological Chemistry, 2000, 275, 37224-37231.	1.6	82
130	Family History of Dementia and Current Depression in Nondemented Community-Dwelling Older Adults. Journal of Geriatric Psychiatry and Neurology, 2000, 13, 65-71.	1.2	3
131	Cholesterol Modulates Vascular Reactivity to Endothelin-1 by Stimulating a Pro-inflammatory Pathway. Biochemical and Biophysical Research Communications, 2000, 274, 553-558.	1.0	22
132	Novel strategies for opposing murine microglial activation. Neuroscience Letters, 2000, 278, 5-8.	1.0	41
133	Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiology of Aging, 2000, 21, 183-197.	1.5	61
134	Vasoactivity of Amyloid $\hat{l}^2$ Peptides. , 2000, , 281-294.		0
135	Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer's disease. Journal of Neuroscience Methods, 1999, 87, 87-95.	1.3	151
136	Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. Journal of Neuroimmunology, 1999, 97, 77-85.	1.1	73
137	Intravascular infusions of soluble β-amyloid compromise the blood–brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Research, 1999, 818, 105-117.	1.1	63
138	Association of a functional ?-opioid receptor allele (+118A) with alcohol dependency. American Journal of Medical Genetics Part A, 1999, 88, 458-461.	2.4	102
139	Alzheimers disease is not associated with the hypertension genetic risk factors PLA2 or G protein ?3, either independently or interactively with apolipoprotein e. American Journal of Medical Genetics Part A, 1999, 88, 465-468.	2.4	4
140	Factors associated with depressive symptoms in non-demented community-dwelling elderly. International Journal of Geriatric Psychiatry, 1999, 14, 331-337.	1.3	34
141	Microglial Activation Resulting from CD40-CD40L Interaction After -Amyloid Stimulation. Science, 1999, 286, 2352-2355.	6.0	340
142	Intravascular β-amyloid infusion increases blood pressure: implications for a vasoactive role of β-amyloid in the pathogenesis of Alzheimer's disease. Neuroscience Letters, 1999, 268, 17-20.	1.0	31
143	Progressive and gender-dependent cognitive impairment in the APPSW transgenic mouse model for Alzheimer's disease. Behavioural Brain Research, 1999, 103, 145-162.	1.2	197
144	Inhibition of Alzheimer's β-Amyloid Induced Vasoactivity and Proinflammatory Response in Microglia by a cGMP-Dependent Mechanism. Experimental Neurology, 1999, 157, 211-221.	2.0	68

#	Article	IF	CITATIONS
145	Alzheimer's β-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Research, 1998, 807, 110-117.	1.1	109
146	Newly described form of X-linked arthrogryposis maps to the long arm of the human X chromosome. , 1998, 78, 450-454.		18
147	The â^'491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neuroscience Letters, 1998, 252, 95-98.	1.0	57
148	Isoform-specific vasoconstriction induced by Apolipoprotein E and modulation of this effect by Alzheimer's β-amyloid peptide. Neuroscience Letters, 1998, 256, 73-76.	1.0	39
149	Role of Peroxynitrite in the Vasoactive and Cytotoxic Effects of Alzheimer's β-Amyloid1–40Peptide. Experimental Neurology, 1998, 152, 116-122.	2.0	33
150	No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample. Neuroscience Letters, 1997, 233, 145-147.	1.0	47
151	Long-Term Venous A?1-40Infusion in Rats Causes Lung Hemorrhage and Brain Perivascular Gliosis. Annals of the New York Academy of Sciences, 1997, 826, 440-446.	1.8	0
152	No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. , 1997, 74, 192-194.		17
153	No association between the intronic presenilin-1 polymorphism and Alzheimer's disease in clinic and population-based samples. , 1997, 74, 202-203.		29
154	No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genetic Epidemiology, 1997, 14, 299-305.	0.6	23
155	Familial and Population-Based Studies of Apolipoprotein E and Alzheimer's Disease. Annals of the New York Academy of Sciences, 1996, 802, 16-26.	1.8	28
156	Dopamine DRD2/Cys311 is not associated with chronic schizophrenia. , 1996, 67, 483-484.		22
157	β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature, 1996, 380, 168-171.	13.7	690
158	Clinical features of early onset, familial Alzheimer's disease linked to chromosome 14. American Journal of Medical Genetics Part A, 1995, 60, 44-52.	2.4	9
159	Occurrence of the Cys311 DRD2 variant in a pedigree multiply affected with panic disorder. American Journal of Medical Genetics Part A, 1995, 60, 332-334.	2.4	17
160	The molecular genetics of Alzheimer's disease. Molecular Neurobiology, 1994, 9, 15-22.	1.9	19
161	THE MOLECULAR GENETICS OF EARLY ONSET FAMILIAL ALZHEIMER'S DISEASE. , 1994, , .		0
162	Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. American Journal of Medical Genetics Part A, 1993, 48, 129-130.	2.4	47

#	Article	IF	CITATIONS
163	Molecular pathology of Alzheimer's disease. International Review of Psychiatry, 1993, 5, 351-362.	1.4	7
164	Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neuroscience Letters, 1992, 137, 221-224.	1.0	87
165	Evidence for Allelic Heterogeneity in Familial Early-Onset Alzheimer's Disease. British Journal of Psychiatry, 1991, 158, 471-474.	1.7	28
166	The role of genetic factors in the etiology of the affective disorders. Behavior Genetics, 1990, 20, 235-250.	1.4	3
167	Molecular genetic studies of manic-depression and schizophrenia. Trends in Neurosciences, 1990, 13, 29-31.	4.2	15
168	The Impact of Molecular Genetics on Our Understanding of the Psychoses. British Journal of Psychiatry, 1989, 154, 591-595.	1.7	16
169	Alcoholism and the 'New Genetics". Addiction, 1989, 84, 1433-1440.	1.7	10